Identification of connective tissue disease autoantibodies and a novel autoantibody anti-annexin A11 in patients with “idiopathic” interstitial lung disease

Sarah Tansley; Fionnuala McMorrow; Caroline Cotton; Huzaifa I. Adamali; Shaney L Barratt; Zoe Betteridge; Janire Perurena-Prieto; Michael A. Gibbons; Raman Kular; Aravinthan Loganathan; Janine A Lamb; Hui Lu; Robert P. New; Diane Pratt; Pilar Rivera-Ortega; Ross Sayers; Matthew Steward; Lachlan Stranks; Edward M Vital; Lisa Spencer; Neil McHugh; Robert G Cooper

doi:10.1016/j.clim.2024.110201

Identification of connective tissue disease autoantibodies and a novel autoantibody anti-annexin A11 in patients with “idiopathic” interstitial lung disease

Sarah Tansley, Fionnuala McMorrow, Caroline Cotton, Huzaifa I. Adamali, Shaney L Barratt, Zoe Betteridge, Janire Perurena-Prieto, Michael A. Gibbons, Raman Kular, Aravinthan Loganathan, Janine A Lamb, Hui Lu, Robert P. New, Diane Pratt, Pilar Rivera-Ortega, Ross Sayers, Matthew Steward, Lachlan Stranks, Edward M Vital, Lisa SpencerNeil McHugh, Robert G Cooper

Research output: Contribution to journal › Article › peer-review

1 Citation (SciVal)

Abstract

Background: Autoantibodies are a hallmark feature of Connective Tissue Diseases (CTD). Their presence in patients with idiopathic interstitial lung disease (ILD) may suggest covert CTD. We aimed to determine the prevalence of CTD autoantibodies in patients diagnosed with idiopathic ILD.

Methods: 499 patient sera were analysed: 251 idiopathic pulmonary fibrosis (IPF), 206 idiopathic non-specific interstitial pneumonia (iNSIP) and 42 cryptogenic organising pneumonia (COP). Autoantibody status was determined by immunoprecipitation.

Results: 2.4% of IPF sera had a CTD-autoantibody compared to 10.2% of iNSIP and 7.3% of COP. 45% of autoantibodies were anti-synthetases. A novel autoantibody targeting an unknown 56 kDa protein was found in seven IPF patients (2.8%) and two NSIP (1%) patients. This was characterised as anti-annexin A11.

Conclusion: Specific guidance on autoantibody testing and interpretation in patients with ILD could improve diagnostic accuracy. Further work is required to determine the clinical significance of anti-annexin A11.

Original language	English
Article number	110201
Journal	Clinical Immunology
Volume	262
Early online date	2 Apr 2024
DOIs	https://doi.org/10.1016/j.clim.2024.110201
Publication status	Published - 31 May 2024

Data Availability Statement

All data can be made available on application to the UK-BILD steering committee.

Funding

This project was supported by a grant from the Liverpool Interstitial Lung Disease Service Charitable Fund. The UK-BILD study has received funding from Arrowe Park Endowment Funds. Funders had no role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; nor in the decision to submit the paper for publication. Research profile myositis line immunoassays were donated by Euroimmun.

Keywords

Autoantibody
Connective tissue disease
Diagnostic assay
Interstitial lung disease
Myositis
Systemic sclerosis

ASJC Scopus subject areas

Immunology and Allergy
Immunology

Access to Document

10.1016/j.clim.2024.110201Licence: CC BY

Cite this

Tansley, S., McMorrow, F., Cotton, C., Adamali, H. I., Barratt, S. L., Betteridge, Z., Perurena-Prieto, J., Gibbons, M. A., Kular, R., Loganathan, A., Lamb, J. A., Lu, H., New, R. P., Pratt, D., Rivera-Ortega, P., Sayers, R., Steward, M., Stranks, L., Vital, E. M., ... Cooper, R. G. (2024). Identification of connective tissue disease autoantibodies and a novel autoantibody anti-annexin A11 in patients with “idiopathic” interstitial lung disease. Clinical Immunology, 262, Article 110201. https://doi.org/10.1016/j.clim.2024.110201

Tansley, S , McMorrow, F, Cotton, C, Adamali, HI, Barratt, SL, Betteridge, Z, Perurena-Prieto, J, Gibbons, MA, Kular, R, Loganathan, A, Lamb, JA, Lu, H, New, RP, Pratt, D, Rivera-Ortega, P, Sayers, R, Steward, M, Stranks, L, Vital, EM, Spencer, L, McHugh, N & Cooper, RG 2024, 'Identification of connective tissue disease autoantibodies and a novel autoantibody anti-annexin A11 in patients with “idiopathic” interstitial lung disease', Clinical Immunology, vol. 262, 110201. https://doi.org/10.1016/j.clim.2024.110201

@article{191a76b402ab4c16aa8a29e19d180a7a,

title = "Identification of connective tissue disease autoantibodies and a novel autoantibody anti-annexin A11 in patients with “idiopathic” interstitial lung disease",

abstract = "Background: Autoantibodies are a hallmark feature of Connective Tissue Diseases (CTD). Their presence in patients with idiopathic interstitial lung disease (ILD) may suggest covert CTD. We aimed to determine the prevalence of CTD autoantibodies in patients diagnosed with idiopathic ILD.Methods: 499 patient sera were analysed: 251 idiopathic pulmonary fibrosis (IPF), 206 idiopathic non-specific interstitial pneumonia (iNSIP) and 42 cryptogenic organising pneumonia (COP). Autoantibody status was determined by immunoprecipitation.Results: 2.4% of IPF sera had a CTD-autoantibody compared to 10.2% of iNSIP and 7.3% of COP. 45% of autoantibodies were anti-synthetases. A novel autoantibody targeting an unknown 56 kDa protein was found in seven IPF patients (2.8%) and two NSIP (1%) patients. This was characterised as anti-annexin A11.Conclusion: Specific guidance on autoantibody testing and interpretation in patients with ILD could improve diagnostic accuracy. Further work is required to determine the clinical significance of anti-annexin A11.",

keywords = "Autoantibody, Connective tissue disease, Diagnostic assay, Interstitial lung disease, Myositis, Systemic sclerosis",

author = "Sarah Tansley and Fionnuala McMorrow and Caroline Cotton and Adamali, {Huzaifa I.} and Barratt, {Shaney L} and Zoe Betteridge and Janire Perurena-Prieto and Gibbons, {Michael A.} and Raman Kular and Aravinthan Loganathan and Lamb, {Janine A} and Hui Lu and New, {Robert P.} and Diane Pratt and Pilar Rivera-Ortega and Ross Sayers and Matthew Steward and Lachlan Stranks and Vital, {Edward M} and Lisa Spencer and Neil McHugh and Cooper, {Robert G}",

year = "2024",

month = may,

day = "31",

doi = "10.1016/j.clim.2024.110201",

language = "English",

volume = "262",

journal = "Clinical Immunology",

issn = "1521-6616",

publisher = "Elsevier Academic Press Inc",

}

TY - JOUR

T1 - Identification of connective tissue disease autoantibodies and a novel autoantibody anti-annexin A11 in patients with “idiopathic” interstitial lung disease

AU - Tansley, Sarah

AU - McMorrow, Fionnuala

AU - Cotton, Caroline

AU - Adamali, Huzaifa I.

AU - Barratt, Shaney L

AU - Betteridge, Zoe

AU - Perurena-Prieto, Janire

AU - Gibbons, Michael A.

AU - Kular, Raman

AU - Loganathan, Aravinthan

AU - Lamb, Janine A

AU - Lu, Hui

AU - New, Robert P.

AU - Pratt, Diane

AU - Rivera-Ortega, Pilar

AU - Sayers, Ross

AU - Steward, Matthew

AU - Stranks, Lachlan

AU - Vital, Edward M

AU - Spencer, Lisa

AU - McHugh, Neil

AU - Cooper, Robert G

PY - 2024/5/31

Y1 - 2024/5/31

N2 - Background: Autoantibodies are a hallmark feature of Connective Tissue Diseases (CTD). Their presence in patients with idiopathic interstitial lung disease (ILD) may suggest covert CTD. We aimed to determine the prevalence of CTD autoantibodies in patients diagnosed with idiopathic ILD.Methods: 499 patient sera were analysed: 251 idiopathic pulmonary fibrosis (IPF), 206 idiopathic non-specific interstitial pneumonia (iNSIP) and 42 cryptogenic organising pneumonia (COP). Autoantibody status was determined by immunoprecipitation.Results: 2.4% of IPF sera had a CTD-autoantibody compared to 10.2% of iNSIP and 7.3% of COP. 45% of autoantibodies were anti-synthetases. A novel autoantibody targeting an unknown 56 kDa protein was found in seven IPF patients (2.8%) and two NSIP (1%) patients. This was characterised as anti-annexin A11.Conclusion: Specific guidance on autoantibody testing and interpretation in patients with ILD could improve diagnostic accuracy. Further work is required to determine the clinical significance of anti-annexin A11.

AB - Background: Autoantibodies are a hallmark feature of Connective Tissue Diseases (CTD). Their presence in patients with idiopathic interstitial lung disease (ILD) may suggest covert CTD. We aimed to determine the prevalence of CTD autoantibodies in patients diagnosed with idiopathic ILD.Methods: 499 patient sera were analysed: 251 idiopathic pulmonary fibrosis (IPF), 206 idiopathic non-specific interstitial pneumonia (iNSIP) and 42 cryptogenic organising pneumonia (COP). Autoantibody status was determined by immunoprecipitation.Results: 2.4% of IPF sera had a CTD-autoantibody compared to 10.2% of iNSIP and 7.3% of COP. 45% of autoantibodies were anti-synthetases. A novel autoantibody targeting an unknown 56 kDa protein was found in seven IPF patients (2.8%) and two NSIP (1%) patients. This was characterised as anti-annexin A11.Conclusion: Specific guidance on autoantibody testing and interpretation in patients with ILD could improve diagnostic accuracy. Further work is required to determine the clinical significance of anti-annexin A11.

KW - Autoantibody

KW - Connective tissue disease

KW - Diagnostic assay

KW - Interstitial lung disease

KW - Myositis

KW - Systemic sclerosis

UR - http://www.scopus.com/inward/record.url?scp=85189540933&partnerID=8YFLogxK

U2 - 10.1016/j.clim.2024.110201

DO - 10.1016/j.clim.2024.110201

M3 - Article

SN - 1521-6616

VL - 262

JO - Clinical Immunology

JF - Clinical Immunology

M1 - 110201

ER -

Identification of connective tissue disease autoantibodies and a novel autoantibody anti-annexin A11 in patients with “idiopathic” interstitial lung disease

Abstract

Data Availability Statement

Funding

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this